Future of Agilent Technologies | Quantumrun

Future of Agilent Technologies

Agilent Technologies, founded in 1999, is an American public research, development, and manufacturing company that was created when it spun off from HP (Hewlett-Packard) Company. The company also provides analytical instruments, software services, and consumables. Agilent's expertise focuses on six key markets: Food, Environmental and Forensics, Pharmaceutical, Diagnostics, Chemical and Energy, and Research. Surprisingly, according to the Silicon Valley history, Agilent's resulting IPO was the largest at the time.

Home Country: 
United States
Industry: 
Healthcare equipment and services
Industry vulnerability to disruption: 

<p>Belonging to the healthcare sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:</p>

<p>*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations.
*However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on subsidized health services (hospitals, emergency care, nursing homes, etc.) to support them in their greying years.<br />
*The economic strain caused this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs, surgeries and treatment protocols that may improve the overall physical and mental health of patients to a point where they can lead independent lives outside of the health care system.<br />
*This increased investment into the health care system will include a greater emphasis on preventative medicine and treatments.<br />
*By the early 2030s, the most profound preventative health care treatment will become available: treatments to stunt and later reverse the effects of aging. These treatments will be provided annually and, over time, will become affordable to the masses. This health revolution will result in a reduced usage and strain on the overall health care system—since younger people/bodies use less health care resources, on average, than people in older, sicker bodies.<br />
*Increasingly, we will use artificial intelligence systems diagnose patients and robots to manage intricate surgeries.<br />
*By the late 2030s, technological implants will correct any physical injury, while brain implants and memory erasure drugs will cure most any mental trauma or illness.<br />
*By the mid-2030s, all medicines will be customized to your unique genome and microbiome.</p>

Total patents held: 
4 235
Number of patents field last year: 
2
Ranking List: 
310
Ranking List: 
2017 Quantumrun Global 1000
209
Ranking List: 
2017 Quantumrun US 500
28
Ranking List: 
2017 Quantumrun Silicon Valley 100
Market Revenue Country: 
Market country 
United States
Revenue from country 
0.30
Market country 
China
Revenue from country 
0.20
Market country 
Other
Revenue from country 
0.50
Prod/Serv name revenue: 
Prod/Serv name: 
Products
Prod/Serv revenue: 
3227000000
Prod/Serv name: 
Services and other
Prod/Serv revenue: 
975000000
Founded: 
1999
Company Name: 
Agilent Technologies
Sector: 
Revenue: 
4202000000
3y average revenue: 
4096000000
Operating expenses: 
1582000000
3y average expenses: 
1552666667
Company profile data note: 
All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page.
Global employee count: 
12500
Number of domestic locations: 
6
Funds in reserve: 
2289000000
Investment into R&D: 
329000000
create term: 
#310 | 2017 Quantumrun Global 1000
#209 | 2017 Quantumrun US 500
#28 | 2017 Quantumrun Silicon Valley 100

Agilent Technologies, founded in 1999, is an American public research, development, and manufacturing company that was created when it spun off from HP (Hewlett-Packard) Company. The company also provides analytical instruments, software services, and consumables. Agilent's expertise focuses on six key markets: Food, Environmental and Forensics, Pharmaceutical, Diagnostics, Chemical and Energy, and Research. Surprisingly, according to the Silicon Valley history, Agilent's resulting IPO was the largest at the time.

Home country:
United States
Sector:
Health Care
Industry:
Healthcare equipment and services
Founded:
1999
Global employee count:
12,500

Financial Health

Revenue
$4,202,000,000 USD
3y average revenue
$4,096,000,000 USD
Operating expenses
$1,582,000,000 USD
3y average expenses
$1,552,666,667 USD
Funds in reserve
$2,289,000,000 USD
#1 Market country
United States
% of revenue from country #1
0.3%
#2 Market country
China
% of revenue from country #2
0.2%
#3 Market country
Other
% of revenue from country #3
0.5%

Asset Performance

#1 Product/Service/Dept. name
Products
#1 Product/Service revenue
$3,227,000,000 USD
#2 Product/Service/Dept. name
Services and other
#2 Product/Service revenue
$975,000,000 USD

Innovation assets and Pipeline

Investment into R&D
$329,000,000 USD
Total patents held
4,235
Number of patents field last year
2
All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page.

Disruption Vulnerability

Belonging to the healthcare sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:

*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations.
*However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on subsidized health services (hospitals, emergency care, nursing homes, etc.) to support them in their greying years.

*The economic strain caused this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs, surgeries and treatment protocols that may improve the overall physical and mental health of patients to a point where they can lead independent lives outside of the health care system.

*This increased investment into the health care system will include a greater emphasis on preventative medicine and treatments.

*By the early 2030s, the most profound preventative health care treatment will become available: treatments to stunt and later reverse the effects of aging. These treatments will be provided annually and, over time, will become affordable to the masses. This health revolution will result in a reduced usage and strain on the overall health care system—since younger people/bodies use less health care resources, on average, than people in older, sicker bodies.

*Increasingly, we will use artificial intelligence systems diagnose patients and robots to manage intricate surgeries.

*By the late 2030s, technological implants will correct any physical injury, while brain implants and memory erasure drugs will cure most any mental trauma or illness.

*By the mid-2030s, all medicines will be customized to your unique genome and microbiome.